3. Phenylenhrine Hydrochloride

S. Martha Meyer; F. T. Fraunfelder

doi:10.1016/S0161-6420(80)35108-7

3. Phenylenhrine Hydrochloride

S. Martha Meyer
, F. T. Fraunfelder

Ophthalmology

Research output: Contribution to journal › Article › peer-review

37 Scopus citations

Abstract

Phenylephrine hydrochloride is a potent, effective, relatively safe drug with few ocular side effects. Side effects from topical instillation are uncommon but include severe systemic cardiovascular effects with elevated blood pressure and stroke. Ten percent phenylephrine should be used with caution in patients with known cardiac disease, hypertension, aneurysms, long-standing insulin-dependent diabetes, or advanced arteriosclerosis. A 2.5% concentration is generally indicated for ophthalmic examination as well as for use in infants and in the elderly. Phenylephrine should not be used in patients with narrow-angle glaucoma, and it is also contraindicated in patients taking monoamine oxidase inhibitors or tricyclic antidepressants.

Original language	English (US)
Pages (from-to)	1177-1180
Number of pages	4
Journal	Ophthalmology
Volume	87
Issue number	11
DOIs	https://doi.org/10.1016/S0161-6420(80)35108-7
State	Published - 1980

Funding

Supported in part by Research to Prevent Blindness, Inc.

Funders
Research to Prevent Blindness

Keywords

anterior uveitis
mydriasis
phenylephrine hydrochloride
secondary glaucoma

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1016/S0161-6420(80)35108-7

Cite this

@article{1777c53685ca4652a87ba0ec0a42d6a6,

title = "3. Phenylenhrine Hydrochloride",

abstract = "Phenylephrine hydrochloride is a potent, effective, relatively safe drug with few ocular side effects. Side effects from topical instillation are uncommon but include severe systemic cardiovascular effects with elevated blood pressure and stroke. Ten percent phenylephrine should be used with caution in patients with known cardiac disease, hypertension, aneurysms, long-standing insulin-dependent diabetes, or advanced arteriosclerosis. A 2.5\% concentration is generally indicated for ophthalmic examination as well as for use in infants and in the elderly. Phenylephrine should not be used in patients with narrow-angle glaucoma, and it is also contraindicated in patients taking monoamine oxidase inhibitors or tricyclic antidepressants.",

keywords = "anterior uveitis, mydriasis, phenylephrine hydrochloride, secondary glaucoma",

author = "Meyer, \{S. Martha\} and Fraunfelder, \{F. T.\}",

note = "Funding Information: Supported in part by Research to Prevent Blindness, Inc.",

year = "1980",

doi = "10.1016/S0161-6420(80)35108-7",

language = "English (US)",

volume = "87",

pages = "1177--1180",

journal = "Ophthalmology",

issn = "0161-6420",

publisher = "Elsevier Inc.",

number = "11",

}

TY - JOUR

T1 - 3. Phenylenhrine Hydrochloride

AU - Meyer, S. Martha

AU - Fraunfelder, F. T.

N1 - Funding Information: Supported in part by Research to Prevent Blindness, Inc.

PY - 1980

Y1 - 1980

N2 - Phenylephrine hydrochloride is a potent, effective, relatively safe drug with few ocular side effects. Side effects from topical instillation are uncommon but include severe systemic cardiovascular effects with elevated blood pressure and stroke. Ten percent phenylephrine should be used with caution in patients with known cardiac disease, hypertension, aneurysms, long-standing insulin-dependent diabetes, or advanced arteriosclerosis. A 2.5% concentration is generally indicated for ophthalmic examination as well as for use in infants and in the elderly. Phenylephrine should not be used in patients with narrow-angle glaucoma, and it is also contraindicated in patients taking monoamine oxidase inhibitors or tricyclic antidepressants.

AB - Phenylephrine hydrochloride is a potent, effective, relatively safe drug with few ocular side effects. Side effects from topical instillation are uncommon but include severe systemic cardiovascular effects with elevated blood pressure and stroke. Ten percent phenylephrine should be used with caution in patients with known cardiac disease, hypertension, aneurysms, long-standing insulin-dependent diabetes, or advanced arteriosclerosis. A 2.5% concentration is generally indicated for ophthalmic examination as well as for use in infants and in the elderly. Phenylephrine should not be used in patients with narrow-angle glaucoma, and it is also contraindicated in patients taking monoamine oxidase inhibitors or tricyclic antidepressants.

KW - anterior uveitis

KW - mydriasis

KW - phenylephrine hydrochloride

KW - secondary glaucoma

UR - https://www.scopus.com/pages/publications/0019226204

UR - https://www.scopus.com/pages/publications/0019226204#tab=citedBy

U2 - 10.1016/S0161-6420(80)35108-7

DO - 10.1016/S0161-6420(80)35108-7

M3 - Article

C2 - 7243210

AN - SCOPUS:0019226204

SN - 0161-6420

VL - 87

SP - 1177

EP - 1180

JO - Ophthalmology

JF - Ophthalmology

IS - 11

ER -

3. Phenylenhrine Hydrochloride

Abstract

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this